• Bayer’s transformation journey embraces agility and flexibility, accelerating therapy delivery to patients
• CMC transformation uses end-to-end expertise and Dynamic Shared Ownership to manage dynamic portfolios
• Global teams in Europe and the US boost efficiency using time zones and talent
• An integration case study demonstrates agile product shifting across development and clinical manufacturing sites
• Sumitra Angepat, VP, Global Biologic Drug Substance, Bayer